Phase III HIV vaccine trial in Thailand: A step toward a protective vaccine for HIV

Expert Review of Vaccines

Volumn 9, Issue 9, 2010, Pages 997-1005

  Vaccari, Monica ^a   Poonam, Poonam ^a   Franchini, Genoveffa ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

gp120; HIV; neutralizing antibodies; Phase III; prime boost; T cell responses; vaccine trial

Indexed keywords

ADJUVANT; ALUMINUM; ENVELOPE PROTEIN; GLYCOPROTEIN GP 120; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; NEUTRALIZING ANTIBODY; PLACEBO; RECOMBINANT PROTEIN; VIRUS VECTOR;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANIMAL EXPERIMENT; ANIMAL MODEL; CANARYPOX VIRUS; CD4 LYMPHOCYTE COUNT; CHIMPANZEE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; GENETIC VARIABILITY; GEOGRAPHIC DISTRIBUTION; HIGH RISK POPULATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN IMMUNODEFICIENCY VIRUS PREVALENCE; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOGENICITY; INFECTION RISK; MACACA; MAJOR CLINICAL STUDY; NONHUMAN; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; REPEATED DRUG DOSE; REVIEW; RHESUS MONKEY; RISK ASSESSMENT; SEXUAL BEHAVIOR; SIMIAN IMMUNODEFICIENCY VIRUS; T LYMPHOCYTE; THAILAND; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; VACCINATION; VIRUS ENVELOPE; VIRUS LOAD; VIRUS RECOMBINANT;

AIDS VACCINES; CANARYPOX VIRUS; CLINICAL TRIALS, PHASE III AS TOPIC; GENETIC VECTORS; HIV INFECTIONS; HUMANS; IMMUNIZATION, SECONDARY; THAILAND; VACCINATION;

EID: 77956481715     PISSN: 14760584     EISSN: 17448395     Source Type: Journal    
DOI: 10.1586/erv.10.104     Document Type: Review

References (75)

1. Burton DR, Desrosiers RC, Doms RW et al. Public health. A sound rationale needed for Phase III HIV-1 vaccine trials. Science 303(5656), 316 (2004).
2. Belshe R, Franchini G, Girard MP et al. Support for the RV144 HIV vaccine trial. Science 305(5681), 177-180 (2004).
3. Health MoP. National Plan for HIV/AIDS Vaccine Development and Evaluation. Department of Communicable Deases Control, Ministry of Public Health, Nonthaburi, Thailand (1993)
4. UNAIDS. Report on the global AIDS epidemic. UNAIDS, Geneva, Switzerland (2008).
5. Phanuphak P, Locharernkul C, Panmuong W, Wilde H. A report of three cases of AIDS in Thailand. Asian Pac. J. Allergy Immunol. 3, 4 (1985).
6. Porapakkham Y, Pramarnpol S, Athicbhoddhi S, Bernhard R. The evolution of HIV/AIDS policy in Thailand: 1984-1994. AIDSCAP policy working paper series, WP5. Family Health International/AIDSCAP/USAID, Washington, DC, USA (1995)
7. UNAIDS. Thailand HIV/AIDS health profle. USAID, Bangkok, Thailand (2008).
8. Nitayaphn S, Brown AE. Preventive HIV vaccine development in Thailand. AIDS 2(Suppl. B), 155-161 (1998).
9. Pitisuttithum P. HIV vaccine research in Thailand: lessons learned. Expert Rev. Vaccines 7(3), 311-317 (2008).
10. Benenson M, Sirisopana N, Amphaipit R et al. Cohort development for future HIV-1 vaccine trials: a community cohort, Chon Buri Province. Thailand. Presented at: AIDS Vaccine 2001. PA, USA, 5-8 September 2001.
11. Markowitz LE, Sirisopana N, Charonwatanachokchai A et al. Feasibility of a preventive HIV-1 vaccine cohort among persons attending sexually transmitted disease clinics in Thailand. J. Acquir. Immune Defc. Syndr. Hum. Retrovirol. 20(5), 488-494 (1999).
12. Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S et al. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N. Engl. J. Med. 361(23), 2209-2220 (2009).
13. Kitayaporn D, Vanichseni S, Mastro TD et al. Infection with HIV-1 subtypes B and E in injecting drug users screened for enrollment into a prospective cohort in Bangkok, Thailand. Syndr. Hum. Retrovirol. 19, 6 (1998).
14. Xiridou M, van Griensven F, Tappero JW et al. The spread of HIV-1 subtypes B and CRF01-AE among injecting drug users in Bangkok, Thailand. J. Acquir. Immune Defc. Syndr. 45(4), 468-475 (2007).
15. VanCott T, Mascola J, Loomis-Price L et al. Cross-subtype neutralizing antibodies induced in baboons by a subtype E gp120 immunogen based on an r5 primary human immunodefciency virus type 1 envelope. J. Virol. 73(6), 10 (1999).
16. Pitisuttithum P, Berman PW, Phonrat B et al. Phase I/II study of a candidate vaccine designed against the B and E subtypes of HIV-1. AIDS 37, 5 (2004).
17. Klein M. AIDS and HIV vaccines. Vaccines 17(2), 5 (1999).
18. Klein M. AIDS vaccines: are we ready for human effcacy trials? JAMA 11, 10 (1997).
19. Kim J, Robb M, Cox J et al. Humoral and cellular HIV-specifc responses induced by the prime-boost combination of aventis-pasteur ALVAC-HIV (vCP205) and oligomeric HIV-1 GP160MN/LAI-2 in HIV-uninfected adults. In: Eighth Conference on Retroviruses and Opportunistic Infections. Chicago, IL, USA (2001)
20. Pitisuttithum P, Gilbert P, Gurwith M et al. Randomized, double-blind, placebo-controlled effcacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand. J. Infect. Dis. 194(12), 10 (2006).
21. Excler JL, Plotkin S. The prime-boost concept applied to HIV preventive vaccines. AIDS 11(Suppl. A), 10 (1997).
22. Clements-Man, Weinhold K, Matthews T et al. Immune responses to human immunodefciency virus (HIV) type 1 induced by canarypox expressing HIV-1MN gp120, HIV-1SF2 recombinant gp120, or both vaccines in seronegative adults. J. Infect. Dis. 177(5), 1230-1246. (1998).
23. Belshe R, Gorse G, Mulligan M et al. Induction of immune responses to HIV-1 by canarypox virus (ALVAC) HIV-1 and gp120 SF-2 recombinant vaccines in uninfected volunteers. NIAID AIDS Vaccine Evaluation Group. AIDS 12(18), 2407-2415 (1998).
24. Sabbaj S, Mulligan MJ, Hsieh RH, Belshe RB, McGhee JR. Cytokine profles in seronegative volunteers immunized with a recombinant canarypox and gp120 prime-boost HIV-1 vaccine. AIDS 14(10), 1365-1374 (2000).
25. Gorse GJ, Patel GB, Belshe RB; National Institute of Allergy and Infectious Diseases HIV Vaccine Trials Network. HIV type 1 vaccine-induced T cell memory and cytotoxic T lymphocyte responses in HIV type 1-uninfected volunteers. AIDS Res. Hum. Retroviruses 17(12), 1175-1189 (2001).
26. Belshe RB, Stevens C, Gorse GJ et al. Safety and immunogenicity of a canarypox-vectored human immunodefciency virus type 1 vaccine with or without gp120: a Phase 2 study in higher-and lower-risk volunteers. J. Infect. Dis. 183(9), 1343-1352 (2001).
27. Nitayaphan S, Pitisuttithum P, Karnasuta C et al. Safety and immunogenicity of an HIV subtype B and E prime-boost vaccine combination in HIV negative Thai adults. J. Infect. Dis. 190(4), 702-706 (2004).
28. Thongcharoen P, Suriyanon V, Paris RM et al. A Phase 1/2 comparative vaccine trial of the safety and immunogenicity of a CRF01-AE (subtype E) candidate vaccine: ALVAC-HIV (vCP1521) prime with oligomeric gp160 (92TH023/LAI-DID) or bivalent gp120 (CM235/SF2) boost. J. Acquir. Immune Defc. Syndr. 46(1), 48-55 (2007).
29. Flynn NM, Harro CD, Judson FN, Mayer KH, Para MF; rgp120 HIV Vaccine Study Group. Placebo-controlled Phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection. J. Infect. Dis. 191(5), 654-665 (2005).
30. Paoletti E, Tartaglia J, Taylor J. Safe and effective poxvirus vectors-NYVAC and ALVAC. Dev. Biol. Stand. 82, 65-69 (1994).
31. Paoletti E, Taylor J, Meignier B, Meric C, Tartaglia J. Highly attenuated poxvirus vectors: NYVAC, ALVAC and TROVAC. Dev. Biol. Stand. 84, 159-163 (1995).
32. Baxby D, Paoletti E. Potential use of non-replicting vectors as recombinant vaccines. Vaccine 10(1), 8-9 (1992).
33. Plotkin SA, Cadoz M, Meignier B et al. The safety and use of canarypox vectored vaccines. Dev. Biol. Stand. 84, 5 (1995).
34. Franchini G, Benson J, Gallo R, Paoletti E, Tartaglia J. Attenuated poxvirus vectors as carriers in vaccines against human T cell leukemia-lymphoma virus type I. AIDS Res. Hum. Retroviruses 12(5), 1 (1996).
35. Taylor J, Meignier B, Tartaglia J et al Biological and immunogenic properties of a canarypox-rabies recombinant, ALVAC-RG (vCP65) in non-avian species. Vaccine 13(6), 539-549 (1995).
36. Egan MA, Pavlat WA, Tartaglia J et al Induction of human immunodefciency virus type 1 (HIV-1)-specifc cytolytic T lymphocyte responses in seronegative adults by a nonreplicating, host-range-restricted canarypox vector (ALVAC) carrying the HIV-1MN env gene. J. Infect. Dis. 171(6), 1623-1627 (1995).
37. Franchini G, Gurunathan S, Baglyos L, Plotkin S, Tartaglia J. Poxvirus-based vaccine candidates for HIV: two decades of experience with special emphasis on canarypox vectors. Expert Rev. Vaccines 3(4 Suppl.), S75-S88 (2004).
38. Carroll MW, Moss B. Poxviruses as expression vectors. Curr. Opin. Biotechnol 8(5), 573 (1997).
39. Barré-Sinoussi F, Chermann JC, Rey F et al Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune defciency syndrome (AIDS). Science 220(4599), 868-871 (1983).
40. Wills JW, Craven RC. Form, function, and use of retroviral gag proteins. AIDS 5 (6), 639-654 (1991).
41. Haffar O, Garrigues J, Travis B, Moran P, Zarling J, Hu SL. Human immunodeficiency virus-like, nonreplicating, gag-env particles assemble in a recombinant vaccinia virus expression system. J. Virol. 64(6), 2653-2659 (1990).
42. Hel Z, Nacsa J, Tsai WP et al. Equivalent immunogenicity of the highly attenuated poxvirus-based ALVAC-SIV and NYVAC-SIV vaccine candidates in SIVmac251-infected macaques. Virology 304(1), 125-134 (2002).
43. Myagkikh M, Alipanah S, Markham PD et al. Multiple immunizations with attenuated poxvirus HIV type 2 recombinants and subunit boosts required for protection of rhesus macaques. AIDS Res. Hum. Retroviruses 12(11), 985-992 (1996).
44. + T-cell responses in vaccinia-experienced SIVmac251-infected macaques. Vaccine 22(5-6), 597-606 (2004).
45. Pal R, Venzon D, Letvin NL et al ALVAC-SIV-gag-pol-env-based vaccination and macaque major histocompatibility complex class I (A*01) delay simian immunodefciency virus SIVmac-induced immunodefciency J. Virol. 76(1), 292-302 (2002).
46. + T-cell loss and reduces both systemic and mucosal simian-human immunodefciency virus SHIVKU2 RNA levels. J. Virol. 80(8), 3732 (2006).
47. Santra S, Schmitz JE, Kuroda MJ et al. Recombinant canarypox vaccine-elicited CTL specifc for dominant and subdominant simian immunodefciency virus epitopes in rhesus monkeys. J. Immunol. 168(4), 1847-1853 (2002).
48. Andersson S, Makitalo B, Thorstensson R et al. Immunogenicity and protective effcacy of a human immunodefciency virus type 2 recombinant canarypox (ALVAC) vaccine candidate in cynomolgus monkeys. J. Infect. Dis. 174(5), 977-985 (1996).
49. Tubiana R, Gomard E, Fleury H et al Vaccine therapy in early HIV-1 infection using a recombinant canarypox virus expressing gp160MN (ALVAC-HIV): a double-blind controlled randomized study of safety and immunogenicity. AIDS 11(6), 819-820 (1997).
50. Kantakamalakul W, De Souza M, Karnasuta C et al. Enhanced sensitivity of detection of cytotoxic T lymphocyte responses to HIV type 1 proteins using an extended in vitro stimulation period for measuring effector function in volunteers enrolled in an ALVAC-HIV Phase I/II prime boost vaccine trial in Thailand. AIDS Res. Hum. Retroviruses 20(6), 642-644 (2004).
51. Marovich MA. ALVAC-HIV vaccines: clinical trial experience focusing on progress in vaccine development. Expert Rev. Vaccines 3(4 Suppl.), S99-S104 (2004).
52. Lee D, Graham BS, Chiu YL et al. Breakthrough infections during Phase 1 and 2 prime-boost HIV-1 vaccine trials with canarypox vectors (ALVAC) and booster dose of recombinant gp120 or gp160. J. Infect. Dis. 190(5), 903-907 (2004).
53. Paris R, Bejrachandra S, Karnasuta C et al. HLA class I serotypes and cytotoxic T-lymphocyte responses among human immunodefciency virus-1-uninfected Thai volunteers immunized with ALVAC-HIV in combination with monomeric gp120 or oligomeric gp160 protein boosting. Tissue Antigens 64(3), 251-256 (2004).
54. Ratto-Kim S, Loomis-Price LD, Aronson N et al. Comparison between env-specifc T-cell epitopic responses in HIV-1-uninfected adults immunized with combination of ALVAC-HIV(vCP205) plus or minus rgp160MN/LAI-2 and HIV-1-infected adults. J. Acquir. Immune Defc. Syndr. 32(1), 9-17 (2003).
55. Pialoux G, Exler J, Rivière Y et al. A prime-boost approach to HIV preventive vaccine using a recombinant canarypox virus expressing glycoprotein 160 (MN) followed by a recombinant glycoprotein 160 (MN/LAI). The AGIS Group, and l'Agence Nationale de Recherche sur le SIDA. AIDS Res. Hum. Retroviruses 11(3), 373-381 (1995).
56. Berman PW, Murthy KK, Wrin T et al. Protection of MN-rgpl20-immunized chimpanzees from heterologous infection with a primary isolate of human immunodefciency virus type 1. J. Infect. Dis. 173(1), 52-59 (1996).
57. Berman PW, Gregory T, Riddle L et al. Protection of chimpanzees from infection by HIV-1 after vaccination with recombinant glycoprotein gp120 but not gp160. Nature 345, 622-625 (1990).
58. Belshe RB, Graham BS, Keefer MC et al. Neutralizing antibodies to HIV-1 in seronegative volunteers immunized with recombinant gp120 from the MN strain of HIV-1. NIAID AIDS Vaccine Clinical Trials Network. JAMA 272(6), 5 (1994).
59. El-Amad Z, Murthy KK, Higgins K et al. Resistance of chimpanzees immunized with recombinant gp120SF2 to challenge by HIV-1SF2. AIDS 9(12), 1313-1322 (1995).
60. Francis DP. AIDSVAX is safe, but effcacy question remains. VaxGen founder discusses quest for AIDS vaccine. AIDS Alert 16(11), 141-142, 147 (2001).
61. Berman PW, Huang W, Lavon Riddle et al. Development of bivalent (B/E) vaccines able to neutralize CCR5-dependent viruses from the United States and Thailand. Virology 265(1), 9 (1999).
62. Francis DP, Gregory T, McElrath MJ et al. Advancing AIDSVAX to Phase 3. Safety, immunogenicity, and plans for Phase 3. AIDS Res. Hum. Retroviruses 14(Suppl. 3), S325-S331 (1998).
63. Harro CD, Judson FN, Gorse GJ et al. VAX004 study group. Recruitment and baseline epidemiologic profle of participants in the frst Phase 3 HIV vaccine effcacy trial. J. Acquir. Immune Defc. Syndr. 37(3), 1385-1392 (2004).
64. + T-cell responses in high-risk, HIV-negative volunteers who subsequently acquire HIV infection. Vaccine 27(7), 1136-1140 (2009).
65. Van Rompay KK, Abel K, Lawson J et al. Attenuated poxvirus-based simian immunodefciency virus (SIV) vaccines given in infancy partially protect infant and juvenile macaques against repeated oral challenge with virulent SIV. J. Acquir. Immune Defc. Syndr. 38(2), 124-134 (2005).
66. Franchini G, Robert-Guroff M, Tartaglia J et al. Highly attenuated HIV type 2 recombinant poxviruses, but not HIV-2 recombinant Salmonella vaccines, induce long-lasting protection in rhesus macaques. AIDS Res. Hum. Retroviruses 11(8), 909-920 (1995).
67. Morgan C, Marthas M, Miller C et al. The use of nonhuman primate models in HIV vaccine development. PLoS Med. 5(8), e173 (2008).
68. Liang X, Schleif WA. Vectored Gag and Env but not Tat show effcacy against simian-human immunodefciency virus 89.6P challenge in mamu-A*01-negative rhesus monkey. J. Virol. 79(19), 12321-12331 (2005).
69. Buchbinder S, Mehrotra DV, Duerr A et al. Effcacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial. Lancet 372, 1881-1893 (2008).
70. Girard M, van der Ryst E, Barré-Sinoussi F et al. Challenge of chimpanzees immunized with a recombinant canarypox-HIV-1 virus. Virology 232(1), 98-104 (1997).
71. Abimiku A, Franchini G, Tartaglia J et al. HIV-1 recombinant poxviruses vaccine induces cross-protection against HIV-2 challenge in rhesus macaques. Nat. Med. 1, 321-329 (1995).
72. Evans TG, McElrath MJ, Matthews T et al. QS-21 promotes an adjuvant effect allowing for reduced antigen dose during HIV-1 envelope subunit immmunization in humans. Vaccine 19(15-16), 2080-2091 (2001).
73. +-T-cell epitopes recognized. J. Virol. 77(20), 11220-11231 (2003).
74. Mugyenyi P. The Uganda experience. Vaccine 20, 1905-1908 (2002).
75. Perez-Losados M, Jobes DV, Sinangil F et al. Phylodynamics of HIV-1 from a Phase-III AIDS Vaccine Trial in North America. Mol. Biol. Evol. 27(2), 417-425 (2010).